First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Mustafa Özgüroğlu, Saadettin Kılıçkap, Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, İrfan Çiçin, Gwo Fuang Ho, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Marina Chiara Garassino, Xuanyao He, Manika Kaul, Emmanuel Chiebuka Okoye, Yuntong Li, Siyu Li, Jean‐François Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel